This content is from: Premium

Hedge funds hemorrhage on InterMune (Magazine Version)

SAC Capital Advisors loaded up on shares of InterMune, a pharmaceutical company, when it looked like the company's hotly anticipated new drug would get approval from the Food and Drug Administration. But when the FDA rejected the drug and the stock plunged 80% in one day, the prognosis for that

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content